Laboratory results on some of the optical properties of Deuteporfin, a relatively new photosensitizing drug that has been in clinical trials in China since around 2009, is discussed. The drug was characterized on the basis of one photon absorption and fluorescence emission for providing data for proper drug applications and dosimetry. In addition, the effects of photobleaching were investigated to characterize decay kinetics. The results of this research on this photosensitizer were also compared against HMME Hematoporphyrin monomethyl ether (HMME) (Hemoporfin®) key characterization data which includes Q-band absorption to compare peak wavelengths and fluorescence intensity to show that Deuteporfin has similar absorption profile to HMME while it has superior fluorescence characteristics. The findings help to support the manufacturer’s claim that Deuteporfin can be an effective photosensitizer for tumor treatment.
|Commitee:||Deng, Yiming, Hamid, Hamid|
|School:||University of Colorado at Denver|
|School Location:||United States -- Colorado|
|Source:||MAI 55/04M(E), Masters Abstracts International|
|Subjects:||Biomedical engineering, Electrical engineering, Optics|
|Keywords:||Deuteporfin, Deuxemether, Photodynamic therapy|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be